Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286624 · ClinicalTrials.gov registry record · Phase 1
Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00286624 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 6 participants.
The verdict
NCT00286624, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study was designed to test the safety and efficacy of up to 3 pancreatic alloislet transplants in type 1 diabetic patients with hypoglycemia unawareness. 6 subjects were transplanted under this protocol using anti-thymocyte globulin induction immunosuppression and everolimus with cyclosporine maintenance immunosuppression.
Interventions
- DRUG Everolimus
- DRUG Cyclosporine
- DRUG anti-thymocyte globulin
- BIOLOGICAL Allogeneic Islets of Langerhans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00286624
The ClinicalTrials.gov registry entry for NCT00286624 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Everolimus is the first listed.
NCT00286624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00286624 about?
NCT00286624 is a clinical study titled "Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation". This study was designed to test the safety and efficacy of up to 3 pancreatic alloislet transplants in type 1 diabetic patients with hypoglycemia unawareness. 6 subjects were transplanted under this protocol using anti-thymocyte globulin induction immunosuppression and everolimus with cyclosporine m...
What is the current status of trial NCT00286624?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2003-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00286624?
The interventions under investigation include: Everolimus (DRUG), Cyclosporine (DRUG), anti-thymocyte globulin (DRUG), Allogeneic Islets of Langerhans (BIOLOGICAL).
Who is sponsoring clinical trial NCT00286624?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.